Between nitros(yl)ation and nitration: Regulation of thioredoxin-1 in myocardial ischemia/reperfusion injury

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 3, 2010, Pages 343-346

  Rassaf, Tienush ^a   Luedike, Peter ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; CYCLOSPORIN A; LINSIDOMINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; THIOREDOXIN 1; THIOREDOXIN INTERACTING PROTEIN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CELLULAR DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TARGETING; EDITORIAL; ENZYME ACTIVE SITE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NITRATION; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; STRUCTURE ACTIVITY RELATION; UPREGULATION;

EID: 77955279147     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.06.001     Document Type: Editorial

References (61)

1. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 1989, 264:13963-13966.
2. Nordberg J., Arner E.S. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001, 31:1287-1312.
3. Hirota K., Nakamura H., Masutani H., Yodoi J. Thioredoxin superfamily and thioredoxin-inducing agents. Ann N Y Acad Sci 2002, 957:189-199.
4. Miranda-Vizuete A., Ljung J., Damdimopoulos A.E., et al. Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. J Biol Chem 2001, 276:31567-31574.
5. Spyrou G., Enmark E., Miranda-Vizuete A., Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 1997, 272:2936-2941.
6. Taniguchi Y., Taniguchi-Ueda Y., Mori K., Yodoi J. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res 1996, 24:2746-2752.
7. Holmgren A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 1995, 3:239-243.
8. Chae H.Z., Chung S.J., Rhee S.G. Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 1994, 269:27670-27678.
9. Yin T., Hou R., Liu S., Lau W.B., Wang H., Tao L. Nitrative inactivation of thioredoxin-1 increases vulnerability of diabetic hearts to ischemia/reperfusion injury. J Mol Cell Cardiol 2010.
10. Yamanaka H., Maehira F., Oshiro M., et al. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 2000, 271:796-800.
11. Liu H., Nishitoh H., Ichijo H., Kyriakis J.M. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 2000, 20:2198-2208.
12. Liu Y., Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 2002, 90:1259-1266.
13. Saitoh M., Nishitoh H., Fujii M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998, 17:2596-2606.
14. Nishiyama A., Matsui M., Iwata S., et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 1999, 274:21645-21650.
15. Schulze P.C., Yoshioka J., Takahashi T., He Z., King G.L., Lee R.T. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004, 279:30369-30374.
16. Hwang C.Y., Ryu Y.S., Chung M.S., et al. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene 2004, 23:8868-8875.
17. Das K.C. c-Jun NH2-terminal kinase-mediated redox-dependent degradation of IkappaB: role of thioredoxin in NF-kappaB activation. J Biol Chem 2001, 276:4662-4670.
18. Schroeder P., Popp R., Wiegand B., Altschmied J., Haendeler J. Nuclear redox-signaling is essential for apoptosis inhibition in endothelial cells-important role for nuclear thioredoxin-1. Arterioscler Thromb Vasc Biol 2007, 27:2325-2331.
19. Crompton M., Ellinger H., Costi A. Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988, 255:357-360.
20. Baines C.P., Kaiser R.A., Purcell N.H., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005, 434:658-662.
21. Skyschally A., Schulz R., Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010, 24:85-87.
22. West M.B., Rokosh G., Obal D., et al. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 2008, 118:1970-1978.
23. Bolli R., Dawn B., Tang X.L., et al. The nitric oxide hypothesis of late preconditioning. Basic Res Cardiol 1998, 93:325-338.
24. Schulz R., Kelm M., Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 2004, 61:402-413.
25. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
26. Zhao Z.Q., Corvera J.S., Halkos M.E., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003, 285:H579-H588.
27. Schulz R., Cohen M.V., Behrends M., Downey J.M., Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res 2001, 52:181-198.
28. Botker H.E., Kharbanda R., Schmidt M.R., et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010, 375:727-734.
29. Zhao Z.Q., Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 2006, 70:200-211.
30. Skyschally A., Schulz R., Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. Herz 2008, 33:88-100.
31. Turoczi T., Chang V.W., Engelman R.M., Maulik N., Ho Y.S., Das D.K. Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol 2003, 35:695-704.
32. Peart J.N., Headrick J.P. Sustained cardioprotection: exploring unconventional modalities. Vascul Pharmacol 2008, 49:63-70.
33. Malik G., Gorbounov N., Das S., et al. Ischemic preconditioning triggers nuclear translocation of thioredoxin and its interaction with Ref-1 potentiating a survival signal through the PI-3-kinase-Akt pathway. Antioxid Redox Signal 2006, 8:2101-2109.
34. Valen G. Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure. Basic Res Cardiol 2004, 99:1-7.
35. Valeur H.S., Valen G. Innate immunity and myocardial adaptation to ischemia. Basic Res Cardiol 2009, 104:22-32.
36. Yamamoto M., Yang G., Hong C., et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003, 112:1395-1406.
37. Shioji K., Kishimoto C., Nakamura H., et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002, 106:1403-1409.
38. Aota M., Matsuda K., Isowa N., Wada H., Yodoi J., Ban T. Protection against reperfusion-induced arrhythmias by human thioredoxin. J Cardiovasc Pharmacol 1996, 27:727-732.
39. Tao L., Gao E., Bryan N.S., et al. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosylation [corrected]. Proc Natl Acad Sci U S A 2004, 101:11471-11476.
40. Hess D.T., Matsumoto A., Kim S.O., Marshall H.E., Stamler J.S. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005, 6:150-166.
41. Lima B., Forrester M.T., Hess D.T., Stamler J.S. S-nitrosylation in cardiovascular signaling. Circ Res 2010, 106:633-646.
42. Haendeler J., Hoffmann J., Tischler V., Berk B.C., Zeiher A.M., Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol 2002, 4:743-749.
43. Haendeler J., Hoffmann J., Zeiher A.M., Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004, 110:856-861.
44. Casagrande S., Bonetto V., Fratelli M., et al. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U S A 2002, 99:9745-9749.
45. Patel R.P., Moellering D., Murphy-Ullrich J., Jo H., Beckman J.S., Darley-Usmar V.M. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 2000, 28:1780-1794.
46. Hogg N., Singh R.J., Kalyanaraman B. The role of glutathione in the transport and catabolism of nitric oxide. FEBS Lett 1996, 382:223-228.
47. Radi R., Peluffo G., Alvarez M.N., Naviliat M., Cayota A. Unraveling peroxynitrite formation in biological systems. Free Radic Biol Med 2001, 30:463-488.
48. Radi R., Beckman J.S., Bush K.M., Freeman B.A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991, 266:4244-4250.
49. Greenacre S.A., Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 2001, 34:541-581.
50. Tao L., Jiao X., Gao E., et al. Nitrative inactivation of thioredoxin-1 and its role in postischemic myocardial apoptosis. Circulation 2006, 114:1395-1402.
51. Luan R., Liu S., Yin T., et al. High glucose sensitizes adult cardiomyocytes to ischaemia/reperfusion injury through nitrative thioredoxin inactivation. Cardiovasc Res 2009, 83:294-302.
52. Wang H.D., Xu S., Johns D.G., et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001, 88:947-953.
53. Wang P., Zweier J.L. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitrite-mediated reperfusion injury. J Biol Chem 1996, 271:29223-29230.
54. Zou M.H., Leist M., Ullrich V. Selective nitration of prostacyclin synthase and defective vasorelaxation in atherosclerotic bovine coronary arteries. Am J Pathol 1999, 154:1359-1365.
55. Rosen P., Nawroth P.P., King G., Moller W., Tritschler H.J., Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001, 17:189-212.
56. Singh R.J., Hogg N., Joseph J., Konorev E., Kalyanaraman B. The peroxynitrite generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors. Arch Biochem Biophys 1999, 361:331-339.
57. Hashemy S.I., Holmgren A. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J Biol Chem 2008, 283:21890-21898.
58. Ichijo H., Nishida E., Irie K., et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275:90-94.
59. Michel M.C., Li Y., Heusch G. Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol 2001, 363:245-266.
60. Milano G., Morel S., Bonny C., et al. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol 2007, 292:H1828-H1835.
61. Schulz R., Belosjorow S., Gres P., Jansen J., Michel M.C., Heusch G. p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc Res 2002, 55:690-700.